BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 14966683)

  • 21. The p53 gene and its role in human brain tumors.
    Bögler O; Huang HJ; Kleihues P; Cavenee WK
    Glia; 1995 Nov; 15(3):308-27. PubMed ID: 8586466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Detection of p53 gene change and serum antibody level in phase II clinical trial of ad p53 gene therapy].
    Zhao M; Xiao SW; Yang JX; Zhang SW; Lü YY
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3495-8. PubMed ID: 16686067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers.
    Müller M; Meyer M; Schilling T; Ulsperger E; Lehnert T; Zentgraf H; Stremmel W; Volkmann M; Galle PR
    Int J Oncol; 2006 Oct; 29(4):973-80. PubMed ID: 16964393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma.
    Gadducci A; Ferdeghini M; Buttitta F; Cosio S; Fanucchi A; Annicchiarico C; Genazzani AR
    Anticancer Res; 1998; 18(5B):3763-5. PubMed ID: 9854491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Serum anti-p53 antibodies in gastric cancer patients].
    Lawniczak M; Bielicki D; Sulzyc-Bielicka V; Marlicz K; Starzyńska T
    Pol Merkur Lekarski; 2007 Sep; 23(135):192-5. PubMed ID: 18080693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients.
    Gumus E; Erdamar S; Demirel G; Horasanli K; Kendirci M; Miroglu C
    Int J Urol; 2004 Dec; 11(12):1070-7. PubMed ID: 15663677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer.
    Tilkin AF; Lubin R; Soussi T; Lazar V; Janin N; Mathieu MC; Lefrère I; Carlu C; Roy M; Kayibanda M
    Eur J Immunol; 1995 Jun; 25(6):1765-9. PubMed ID: 7615005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative assessment of the functional p53 status in glioma cells.
    Kim EL; Yoshizato K; Kluwe L; Meissner H; Warnecke G; Zapf S; Westphal M; Deppert W; Giese A
    Anticancer Res; 2005; 25(1A):213-24. PubMed ID: 15816541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection.
    Megliorino R; Shi FD; Peng XX; Wang X; Chan EK; Tan EM; Zhang JY
    Cancer Detect Prev; 2005; 29(3):241-8. PubMed ID: 15896923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum anti-p53 autoantibodies from patients with idiopathic pulmonary fibrosis associated with lung cancer.
    Oshikawa K; Sugiyama Y
    Respir Med; 2000 Nov; 94(11):1085-91. PubMed ID: 11127496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutated p53 in tumors, mutant p53 and p53-specific antibodies in the circulation in patients with gastric cancer.
    Maeta M; Saito H; Oka S; Tsujitani S; Ikeguchi M; Kaibara N
    J Exp Clin Cancer Res; 2000 Dec; 19(4):489-95. PubMed ID: 11277328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.
    Creaney J; McLaren BM; Stevenson S; Musk AW; de Klerk N; Robinson BW; Lake RA
    Br J Cancer; 2001 Jan; 84(1):52-6. PubMed ID: 11139313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The circulating auto-antibodies to p53 protein in the follow-up of lymphoma patients.
    Jezersek B; Rudolf Z; Novakovic S
    Oncol Rep; 2001; 8(1):77-81. PubMed ID: 11115573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene p53 mutations, protein p53, and anti-p53 antibodies as biomarkers of cancer process.
    Lutz W; Nowakowska-Swirta E
    Int J Occup Med Environ Health; 2002; 15(3):209-18. PubMed ID: 12462448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-p53 antibodies and p53 protein expression in cholangiocarcinoma.
    Limpaiboon T; Sripa B; Wongkham S; Bhudhisawasdi V; Chau-in S; Teerajetgul Y
    Hepatogastroenterology; 2004; 51(55):25-8. PubMed ID: 15011824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors.
    Ren ZP; Olofsson T; Qu M; Hesselager G; Soussi T; Kalimo H; Smits A; Nistér M
    J Neuropathol Exp Neurol; 2007 Oct; 66(10):944-54. PubMed ID: 17917588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p53 Antibodies in the sera of patients with various types of cancer: a review.
    Soussi T
    Cancer Res; 2000 Apr; 60(7):1777-88. PubMed ID: 10766157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival.
    Bergqvist M; Brattström D; Larsson A; Hesselius P; Brodin O; Wagenius G
    BMC Cancer; 2004 Sep; 4():66. PubMed ID: 15367333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.
    Gao RJ; Bao HZ; Yang Q; Cong Q; Song JN; Wang L
    Breast Cancer Res Treat; 2005 Sep; 93(2):111-5. PubMed ID: 16187230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isolation of human antibodies against the central DNA binding domain of p53 from an individual with colorectal cancer using antibody phage display.
    Coomber DW; Ward RL
    Clin Cancer Res; 2001 Sep; 7(9):2802-8. PubMed ID: 11555596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.